Welcome to our dedicated page for Dice Therapeutics news (Ticker: DICE), a resource for investors and traders seeking the latest updates and insights on Dice Therapeutics stock.
DICE Therapeutics, Inc. (NASDAQ: DICE) is a clinical-stage biopharmaceutical company pioneering oral therapies for chronic immunological conditions through its proprietary DELSCAPE technology. Following its pending acquisition by Eli Lilly and Company, DICE remains focused on advancing innovative treatments that combine the efficacy of biologics with the convenience of oral administration.
This resource provides investors and healthcare professionals with timely updates on DICE's clinical developments, regulatory milestones, and strategic initiatives. Users will find verified information on key areas including progress of IL-17 inhibitors for autoimmune disorders, advancements in inflammatory bowel disease therapies, and integration updates related to the Eli Lilly partnership.
All content is curated to support informed decision-making while maintaining strict compliance with financial disclosure standards. Bookmark this page for centralized access to DICE's official announcements, ensuring you stay current with developments impacting both patient care and investment considerations in the biopharmaceutical sector.
DICE Therapeutics, a biopharmaceutical company traded on Nasdaq under the symbol DICE, announced its participation in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, scheduled for March 30, 2023, at 4:00 p.m. ET. The event will focus on DICE's novel oral therapeutic candidates targeting chronic diseases in immunology, utilizing its proprietary DELSCAPE technology platform. A live and archived webcast will be available for 90 days post-event on the company's website. DICE is dedicated to developing effective oral treatments against key immunology targets like IL-17 and integrin α4ß7, aiming to match systemic biologics' potency.
DICE Therapeutics, Inc. (Nasdaq: DICE) announced significant advancements in its clinical pipeline, highlighted by the FDA's clearance of the IND application for its lead oral IL-17 antagonist, DC-806. A global Phase 2b trial for DC-806 in psoriasis is set to begin in 1H 2023. Additionally, the company has initiated a Phase 1 trial for its second oral IL-17 antagonist, DC-853, with topline data expected in 2H 2023. As of December 31, 2022, DICE reported a robust cash position of $574.2 million, projected to fund operations through 2026 and important clinical milestones.
DICE Therapeutics, Inc. (Nasdaq: DICE) announced that data from its Phase 1 clinical trial of DC-806 will be presented at the 2023 American Academy of Dermatology Annual Meeting on March 18, 2023. DC-806 is a small molecule antagonist targeting IL-17, which plays a crucial role in psoriasis. This presentation aims to showcase the proof-of-concept findings for treating mild-to-moderate psoriasis. DICE plans to advance DC-806 into a Phase 2b clinical trial in the first half of 2023, following positive Phase 1 results. The company focuses on developing oral therapeutics for chronic conditions, including psoriasis, inflammatory bowel disease, and idiopathic pulmonary fibrosis.
DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company specializing in oral therapeutics for chronic diseases, announced participation in two major investor conferences. The SVB Securities Global Biopharma Conference features a fireside chat on February 14, 2023, at 2:20 p.m. ET, followed by the 43rd Annual Cowen Healthcare Conference dermatology panel on March 7, 2023, at 12:50 p.m. ET. Live and archived webcasts of these presentations will be available for 90 days on the company’s website. DICE focuses on developing novel oral candidates targeting immunology, aiming for comparable effectiveness to existing biologics.
FAQ
What is the market cap of Dice Therapeutics (DICE)?
